BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2710 related articles for article (PubMed ID: 31115369)

  • 1. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidemiology of non-alcoholic fatty liver disease.
    Bellentani S
    Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
    Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
    Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Margini C; Dufour JF
    Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should Patients With NAFLD/NASH Be Surveyed for HCC?
    Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
    Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.
    Huang DQ; El-Serag HB; Loomba R
    Nat Rev Gastroenterol Hepatol; 2021 Apr; 18(4):223-238. PubMed ID: 33349658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 136.